AORT
Artivion, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 400 | $8,764 | n/a | −1 |
| Q2 2026 | 77 | -8 | 30.79M | $692.37M | +4 | −14 |
| Q1 2026 | 90 | -2 | 28.88M | $1.06B | +3 | −5 |
| Q4 2025 | 92 | +1 | 30.30M | $1.38B | +1 | n/a |
| Q3 2025 | 16 | 0 | 19.46M | $824.05M | n/a | n/a |
| Q2 2025 | 13 | -1 | 15.74M | $489.42M | n/a | −1 |
| Q1 2025 | 11 | +2 | 4.47M | $109.76M | +4 | −2 |
| Q4 2024 | 9 | 0 | 4.55M | $130.11M | +2 | −2 |
| Q3 2024 | 8 | -1 | 2.82M | $75.02M | n/a | −1 |
| Q2 2024 | 9 | n/a | 3.19M | $81.86M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 6.05M | +0.8% | $256.14M | 0.0% | ▲ Add | 2 | SEC ↗ ×12 |
| 2 | The Vanguard Group ✦ (passive) | 3.03M | +8.3% | $128.25M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | Fidelity (FMR) ✦ | 2.99M | +30.6% | $126.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 4 | Morgan Stanley ✦ | 2.24M | n/a | $94.78M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 5 | State Street Global Advisors ✦ (passive) | 1.54M | +1.7% | $65.22M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.50M | -12.4% | $63.56M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 7 | Geode Capital Management ✦ (passive) | 931.62K | +5.2% | $39.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 446.54K | +235.5% | $18.91M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | JPMorgan Chase ✦ | 244.40K | n/a | $10.35M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 10 | Goldman Sachs Group ✦ | 219.86K | n/a | $9.31M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 11 | Millennium Management ✦ | 90.92K | -36.1% | $3.85M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 82.85K | -45.9% | $3.51M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 40.03K | -7.7% | $1.70M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Marshall Wace ✦ | 28.53K | -9.5% | $1.21M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 15 | AQR Capital Management ✦ | 16.23K | -18.1% | $687,222 | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 16 | Gotham Asset Management ✦ | 14.72K | 0.0% | $623,329 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 237 holders, 44.31M shares, $1.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.48K sh · $286,656
Officer · 1.49K sh · $38,842
Officer · 6.51K sh · $177,495
Officer · 70.00K sh · $2.03M
Officer · 715 sh · $20,413
Officer · 616 sh · $17,586
Officer · 977 sh · $27,835
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology